Which has higher valuation & earnings, ABVX or CDNA?

CareDx has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A CareDx $458.09M 6.08 -$21.35M $2.07 26.00

Is ABVX or CDNA more profitable?

CareDx has a net margin of 24.23% compared to Abivax's net margin of 0.00%. CareDx's return on equity of 2.87% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% CareDx 24.23% 2.87% 2.17%

Does the media favor ABVX or CDNA?

In the previous week, Abivax had 1 more articles in the media than CareDx. MarketBeat recorded 4 mentions for Abivax and 3 mentions for CareDx. CareDx's average media sentiment score of 0.88 beat Abivax's score of 0.51 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CareDx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, KRYS or CDNA?

Krystal Biotech has higher earnings, but lower revenue than CareDx. CareDx is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $440.48M 22.62 $204.83M $7.98 42.19 CareDx $458.09M 6.08 -$21.35M $2.07 26.00

Is KRYS or CDNA more profitable?

Krystal Biotech has a net margin of 54.82% compared to CareDx's net margin of 24.23%. Krystal Biotech's return on equity of 19.34% beat CareDx's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 54.82% 19.34% 17.65% CareDx 24.23% 2.87% 2.17%

Does the media prefer KRYS or CDNA?

In the previous week, Krystal Biotech and Krystal Biotech both had 3 articles in the media. Krystal Biotech's average media sentiment score of 1.65 beat CareDx's score of 0.88 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CareDx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CDNA or PTGX?

In the previous week, CareDx had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 3 mentions for CareDx and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.75 beat CareDx's score of 0.88 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CareDx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings & valuation, KYMR or CDNA?

CareDx has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kymera Therapeutics $39.21M 249.70 -$311.35M -$3.24 N/A CareDx $458.09M 6.08 -$21.35M $2.07 26.00

Does the media favor KYMR or CDNA?

In the previous week, Kymera Therapeutics had 4 more articles in the media than CareDx. MarketBeat recorded 7 mentions for Kymera Therapeutics and 3 mentions for CareDx. CareDx's average media sentiment score of 0.88 beat Kymera Therapeutics' score of 0.57 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CareDx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRAX or CDNA?

In the previous week, CareDx had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 3 mentions for CareDx and 1 mentions for Praxis Precision Medicines. CareDx's average media sentiment score of 0.88 beat Praxis Precision Medicines' score of 0.75 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CareDx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CareDx (CDNA) Competitors

$53.83 -0.45 (-0.83%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$54.00 +0.17 (+0.32%)

As of 09/18/2026 07:30 PM Eastern

Compare

CDNA vs. ABVX, KRYS, PTGX, KYMR, and PRAX

Should you buy CareDx stock or one of its competitors? CareDx's main competitors and comparable companies include Abivax (ABVX), Krystal Biotech (KRYS), Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), and Praxis Precision Medicines (PRAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CareDx compare to Abivax?

Abivax (NASDAQ:ABVX) and CareDx (NASDAQ:CDNA) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Abivax currently has a consensus price target of $156.38, indicating a potential upside of 48.88%. CareDx has a consensus price target of $51.20, indicating a potential downside of 4.89%. Given Abivax's stronger consensus rating and higher probable upside, analysts clearly believe Abivax is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

In the previous week, Abivax had 1 more articles in the media than CareDx. MarketBeat recorded 4 mentions for Abivax and 3 mentions for CareDx. CareDx's average media sentiment score of 0.88 beat Abivax's score of 0.51 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CareDx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CareDx has a net margin of 24.23% compared to Abivax's net margin of 0.00%. CareDx's return on equity of 2.87% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
CareDx	24.23%	2.87%	2.17%

Abivax has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, CareDx has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. 2.4% of CareDx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CareDx has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
CareDx	$458.09M	6.08	-$21.35M	$2.07	26.00

Summary

CareDx beats Abivax on 10 of the 15 factors compared between the two stocks.

How does CareDx compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and CareDx (NASDAQ:CDNA) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Krystal Biotech has a net margin of 54.82% compared to CareDx's net margin of 24.23%. Krystal Biotech's return on equity of 19.34% beat CareDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
CareDx	24.23%	2.87%	2.17%

Krystal Biotech has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, CareDx has a beta of 2.43, suggesting that its share price is 143% more volatile than the broader market.

Krystal Biotech presently has a consensus target price of $365.40, indicating a potential upside of 8.53%. CareDx has a consensus target price of $51.20, indicating a potential downside of 4.89%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

Krystal Biotech has higher earnings, but lower revenue than CareDx. CareDx is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$440.48M	22.62	$204.83M	$7.98	42.19
CareDx	$458.09M	6.08	-$21.35M	$2.07	26.00

86.3% of Krystal Biotech shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 2.4% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Krystal Biotech and Krystal Biotech both had 3 articles in the media. Krystal Biotech's average media sentiment score of 1.65 beat CareDx's score of 0.88 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CareDx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats CareDx on 13 of the 15 factors compared between the two stocks.

How does CareDx compare to Protagonist Therapeutics?

CareDx (NASDAQ:CDNA) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, CareDx had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 3 mentions for CareDx and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.75 beat CareDx's score of 0.88 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CareDx currently has a consensus price target of $51.20, indicating a potential downside of 4.89%. Protagonist Therapeutics has a consensus price target of $147.13, indicating a potential upside of 2.89%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

Protagonist Therapeutics has a net margin of 29.40% compared to CareDx's net margin of 24.23%. Protagonist Therapeutics' return on equity of 12.03% beat CareDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	24.23%	2.87%	2.17%
Protagonist Therapeutics	29.40%	12.03%	11.23%

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 2.4% of CareDx shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CareDx has a beta of 2.43, suggesting that its share price is 143% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

CareDx has higher revenue and earnings than Protagonist Therapeutics. CareDx is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$458.09M	6.08	-$21.35M	$2.07	26.00
Protagonist Therapeutics	$281.99M	32.81	-$130.15M	$1.03	138.83

Summary

Protagonist Therapeutics beats CareDx on 11 of the 17 factors compared between the two stocks.

How does CareDx compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and CareDx (NASDAQ:CDNA) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Kymera Therapeutics has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. Comparatively, CareDx has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market.

Kymera Therapeutics currently has a consensus price target of $131.63, indicating a potential upside of 11.78%. CareDx has a consensus price target of $51.20, indicating a potential downside of 4.89%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Kymera Therapeutics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.88
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

In the previous week, Kymera Therapeutics had 4 more articles in the media than CareDx. MarketBeat recorded 7 mentions for Kymera Therapeutics and 3 mentions for CareDx. CareDx's average media sentiment score of 0.88 beat Kymera Therapeutics' score of 0.57 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CareDx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CareDx has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	249.70	-$311.35M	-$3.24	N/A
CareDx	$458.09M	6.08	-$21.35M	$2.07	26.00

CareDx has a net margin of 24.23% compared to Kymera Therapeutics' net margin of -285.33%. CareDx's return on equity of 2.87% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
CareDx	24.23%	2.87%	2.17%

Summary

CareDx beats Kymera Therapeutics on 9 of the 14 factors compared between the two stocks.

How does CareDx compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and CareDx (NASDAQ:CDNA) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

CareDx has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	976.22	-$303.27M	-$12.93	N/A
CareDx	$458.09M	6.08	-$21.35M	$2.07	26.00

Praxis Precision Medicines presently has a consensus target price of $612.42, indicating a potential upside of 104.86%. CareDx has a consensus target price of $51.20, indicating a potential downside of 4.89%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

Praxis Precision Medicines has a beta of 2.76, indicating that its stock price is 176% more volatile than the broader market. Comparatively, CareDx has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 2.4% of CareDx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, CareDx had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 3 mentions for CareDx and 1 mentions for Praxis Precision Medicines. CareDx's average media sentiment score of 0.88 beat Praxis Precision Medicines' score of 0.75 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CareDx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CareDx has a net margin of 24.23% compared to Praxis Precision Medicines' net margin of 0.00%. CareDx's return on equity of 2.87% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
CareDx	24.23%	2.87%	2.17%

Summary

CareDx beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

Get CareDx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDNA vs. The Competition

Export

Metric	CareDx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.78B	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	26.00	14.23	275.49	25.40
Price / Sales	6.08	1,440.84	644.44	86.30
Price / Cash	8,264.50	108.90	76.25	51.42
Price / Book	9.14	15.45	10.46	6.33
Net Income	-$21.35M	-$22.86M	$3.49B	$358.33M
7 Day Performance	7.10%	-1.21%	0.59%	1.12%
1 Month Performance	14.56%	-3.29%	-1.74%	-2.39%
1 Year Performance	268.95%	37.74%	18.13%	5.35%

CareDx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDNA CareDx	2.7655 of 5 stars	$53.83 -0.8%	$51.20 -4.9%	+269.0%	$2.78B	$379.80M	316.65	765
ABVX Abivax	2.3245 of 5 stars	$113.58 -4.3%	$156.38 +37.7%	+27.6%	$10.35B	N/A	N/A	69	Positive News Upcoming Earnings
KRYS Krystal Biotech	3.6578 of 5 stars	$340.03 -2.0%	$365.40 +7.5%	+105.8%	$10.27B	$389.13M	42.61	295	Positive News
PTGX Protagonist Therapeutics	1.8875 of 5 stars	$147.78 -0.3%	$147.13 -0.4%	+129.9%	$9.59B	$46.02M	143.48	141	Positive News
KYMR Kymera Therapeutics	1.6592 of 5 stars	$114.63 -0.3%	$131.63 +14.8%	+139.7%	$9.56B	$105M	N/A	273

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDNA) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CareDx (CDNA) Competitors

CDNA vs. ABVX, KRYS, PTGX, KYMR, and PRAX

How does CareDx compare to Abivax?

Summary

How does CareDx compare to Krystal Biotech?

Summary

How does CareDx compare to Protagonist Therapeutics?

Summary

How does CareDx compare to Kymera Therapeutics?

Summary

How does CareDx compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDNA vs. The Competition

CareDx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CareDx (CDNA) Competitors

CDNA vs. ABVX, KRYS, PTGX, KYMR, and PRAX

How does CareDx compare to Abivax?

Do analysts recommend ABVX or CDNA?

Does the media favor ABVX or CDNA?

Is ABVX or CDNA more profitable?

Which has more risk & volatility, ABVX or CDNA?

Do insiders & institutionals believe in ABVX or CDNA?

Which has higher valuation & earnings, ABVX or CDNA?

Summary

How does CareDx compare to Krystal Biotech?

Is KRYS or CDNA more profitable?

Which has more volatility and risk, KRYS or CDNA?

Do analysts rate KRYS or CDNA?

Which has preferable earnings & valuation, KRYS or CDNA?

Do insiders and institutionals believe in KRYS or CDNA?

Does the media prefer KRYS or CDNA?

Summary

How does CareDx compare to Protagonist Therapeutics?

Does the media favor CDNA or PTGX?

Do analysts prefer CDNA or PTGX?

Is CDNA or PTGX more profitable?

Do institutionals & insiders have more ownership in CDNA or PTGX?

Which has more risk and volatility, CDNA or PTGX?

Which has better valuation and earnings, CDNA or PTGX?

Summary

How does CareDx compare to Kymera Therapeutics?

Which has more volatility and risk, KYMR or CDNA?

Do analysts prefer KYMR or CDNA?

Does the media favor KYMR or CDNA?

Which has stronger earnings & valuation, KYMR or CDNA?

Is KYMR or CDNA more profitable?

Summary

How does CareDx compare to Praxis Precision Medicines?

Which has stronger valuation and earnings, PRAX or CDNA?

Do analysts rate PRAX or CDNA?

Which has more risk & volatility, PRAX or CDNA?

Do institutionals & insiders believe in PRAX or CDNA?

Does the media refer more to PRAX or CDNA?

Is PRAX or CDNA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDNA vs. The Competition

CareDx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools